Floatz logo

Fluciclatide

Kidney Neoplasms

National Cancer Institute (NCI)protein_peptidePhase 1/2Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Kidney Neoplasms cohort.

Asset / SponsorPhaseRating
Axitinib
Pfizer
Phase 3BB
Ipilimumab
Pfizer
Phase 4BB
Nivolumab
Bristol-Myers Squibb
Phase 4BB
Inno-206
Merck Sharp & Dohme LLC
Phase 2BB
Sorafenib
Pfizer
Phase 3B

View all 50 →

Same molecule, other indications

Fluciclatide is also rated in:

malignant gliomaDormant
CCC
Indicative ·
50 / 100
View asset →
head and neck cancerDormant
CCC
Indicative ·
50 / 100
View asset →
lung cancerDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →